In the age of precision medicine, targeted drugs are transforming cancer treatment. But cancer cells persist in many patients, even in breast cancer, where much-lauded hormone therapies and targeted ...
In 2020, news headlines repeated John Moult’s words at the end of a stunning competition: Artificial intelligence had “solved” a long-standing grand challenge in biology, protein structure prediction.
Itovebi, combined with Ibrance and Faslodex, is approved for specific advanced breast cancer cases with PIK3CA mutations. The INAVO120 trial showed Itovebi significantly improved progression-free ...
The developers of OpenFold3 have released an early version of the tool, which they hope will one day perform on par with DeepMind’s protein-structure model.
A three-decade-old competition that has spawned three Nobel laureates is becoming victim to the chaos at the National Institutes of Health. The Community Wide Experiment on the Critical Assessment of ...
AlphaFold3 uses AI to helps scientists more accurately predict how proteins interact with other biological molecules. When you purchase through links on our site, we may earn an affiliate commission.
Itovebi, approved for some patients with breast cancer, is the first PI3K inhibitor to display a survival benefit, according to Dr. Kevin Kalinsky. Kalinsky is a professor and director in the Division ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback